AbbVie stock forecast 2025 examines healthcare spending trends, anticipating higher demand for immunology products globally. Analysts note this trend could shield ABBV from cyclical market risks. AbbVie Inc. (NYSE: ABBV ) ranks among the stocks with low beta that can beat market volatility . On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had reached a settlement that would allow generic Rinvoq to be introduced in April 2037, over four years later than Leerink had previously predicted. Recent discussions on X about AbbVie (ABBV) have centered around the company’s strong performance in the pharmaceutical sector, particularly following reports of a significant stock price increase and consistent sales growth. Many users have highlighted the stock’s recent surge to over $190 per share, with some pointing to quarterly sales growth figures as a key driver of interest. There’s also buzz about AbbVie’s robust portfolio of drugs and its status as a dividend standout, sparking conversations about long-term potential. The AbbVie stock forecast 2025 from sector specialists incorporates expectations of regulatory approvals for novel migraine and oncology treatments. This could help sustain revenue momentum above $65 billion annually, maintaining ABBV’s large-cap growth profile.
